Showing posts with label Animal Cruelty. Show all posts
Showing posts with label Animal Cruelty. Show all posts

Monday, June 21, 2021

Globe Masks Child Abuse

In the past this would have been tagged a Slow Saturday Special; however, there is no longer anything special about the Globe on any day.

In this case, it was the horror I found straddling the fold this past Saturday:

"The downside of ditching masks: the return of colds, flu" by Camille Caldera Globe Correspondent, June 14, 2021

[The name looks new to me. I wonder who they pushed out]

Since the state’s mask mandate was lifted at the end of May, face coverings have started to come off — and stay off, but according to infectious diseases doctors, the return of facial freedom might come with some downsides, like a resurgence in cases of the common cold and the flu.

Throughout the pandemic, precautions taken to stop the spread of COVID-19 all but eliminated other common viruses.

So far this flu season, the Centers for Disease Control and Prevention has reported just one influenza-associated pediatric death nationwide, compared with 199 the previous season, and a study published in September in the CDC’s Morbidity and Mortality Weekly Report revealed a staggering 98 percent decrease in flu activity in the first months of the pandemic.

[There really is no limit to their audacity in the way they spin the renaming of seasonal cold and flu into the scary CVD!

I know the correspondent is a newby, but this is insulting beyond the limit. Lies turned upside down are still lies.

Honestly, there is only one term to describe it, sigh]

“Most of us in infectious disease really attributed that to masks — not just masks, but the combination of masks, people working largely from home, social distancing, all of those measures that have been in place for the last year,” said Dr. Joshua Barocas, an infectious diseases physician at Boston Medical Center, but as vaccination rates increase and such precautions are slowly scrapped, other viruses will start to resurge, starting with colds and other viruses later this summer, and the flu come fall and winter.

On Thursday, the Centers for Disease Control and Prevention issued a health advisory about increased cases of respiratory syncytial virus, or RSV, across parts of the southern United States — something they hadn’t seen since April 2020, when cases “decreased rapidly.” RSV is a cold-like respiratory illness that produces symptoms similar to COVID, and can cause severe illness in older adults and young children.

[Ironically, the disease from wearing an unhealthy and unnecessary mask]

Since late March — about the time COVID vaccines began to be widely available — cases of RSV have been on the rise in the South. Though the trend hasn’t yet reached the North, where the public was slower to unmask en masse because of lingering restrictions, experts predict that it will.

“I imagine it’s going to start expanding to all of the other states as well, as the mask mandates are lifted and as people start socializing more and spending more time together,” said Dr. Helen Chu, an infectious disease specialist at the University of Washington. 

Chu predicted that the return of viruses like RSV and influenza could be somewhat mitigated by the continuation of public health measures in schools this fall.

Masks are among the most effective of such measures, she said, because much of virus transmission is droplet based, expelled from one person’s mouth or nose and into another’s.

“Having that mask on prevents that type of droplet-based transmission pretty well,” Chu said.

[Oh, she is what is now viewed as a criminal for pushing this fraud, especially when the distance for the little superspreaders who rarely contract or transmit it.

The last people on this planet that should be wearing masks are children under the age of 20 who are still developing. It is depriving them of vital oxygen that will stunt their physical growth and damage their brain, with the side benefit of making them sick with respiratory di$ea$es that can then be diagnosed as.... (drum roll).... CVD.

What an evil, criminal, mass-murdering racket!]

For that reason, Barocas said he will likely continue to wear a face mask in situations that present an elevated risk of cold or flu transmission — like a large holiday gathering or night out at a crowded bar.

“I want to lower my risk of respiratory infection. I don’t really want to miss work,” Barocas said, “and to me, wearing a mask is such low-hanging fruit that I’ll probably do it in a lot of social situations.”

He also noted the protection face masks afford from pollutants in the air and common allergens like pollen.

[How in the world has humanity not only made it to this point, but flourished to the point of needing the be culled and depopulated by these $ick mon$ters, huh?]

Dr. Nahid Bhadelia, the founding director of the Boston University Center for Emerging Infectious Diseases Policy and Research, said she recommends her patients keep their masks on hand. 

Chu agreed with that advice, and added that she and other infectious disease doctors are concerned about how children will handle the upcoming flu season.

“All of us in infectious diseases are just holding our breath right now to see what happens when the flu comes back, because it is heading into an environment where children have not seen it,” she said. “For many of them, this will be their first exposure, and I’m just worried about how sick they might get once they get it.”

Barocas anticipates sending his children to school with masks this fall, regardless of whether or not their schools require them.

“Quite honestly, it’s been really nice not having my kids have the colds and sore throats that keep them home from school, and it’s highly likely that my wife and I will encourage our kids to bring their masks to school and wear them for part of the day,” he said. “At the very least, it’s going to reduce their risk a little bit.”

[MASK OFF!]


My advice is avoid the classroom at all costs (btw, that link came with this ad)

The next question was whether to go up above the fold, or down below.

In either case, their is unmitigated evil to be found.

{@@##$$%%^^&&}

I looked toward Heaven first:


That's the first time I have seen him in a Bo$ton Globe pew.

I turn to the right and see this:


The New York Times took the Dias to absolve Biden who, sniff-sniff, has the stench of pettofeelya, iynwim.

{@@##$$%%^^&&}

Then I looked down:


A drink always makes me feel a bit Cheeky:

"Starting Saturday, businesses including stores, bars, restaurants, casinos, and gyms are able to operate at full capacity, and high-contact establishments like nightclubs can open for the first time since the start of the pandemic. Vaccinated people can drop their masks indoors, except in riskier settings such as hospitals and public transportation. The lifting of the rules marks a major step in the state’s recovery from COVID-19. Some establishments quite literally rang in the new era. A DJ at Cheeky Monkey Brewing Co. on Lansdowne Street was set to count down the seconds until midnight. As Friday night became Saturday morning, the brewpub hoped to reach its full capacity of 575 people, employees planned to knock down plexiglass barriers, and customers were to be allowed to party maskless until 2 a.m., but while some industries celebrate a dramatic return to something like normal, people in other sectors warn that some effects of the crisis will take longer to unwind. “Labor Day is still kind of that sweet spot for the companies we’re talking to,” said Liz Berthelette, research director at real estate firm Newmark. State Senator Julian Cyr, a Truro Democrat, said he’s already hearing that Cape Cod businesses including some dance clubs, will require patrons to provide proof of vaccination upon entry to protect other patrons and workers at the venues. Nonetheless, Encore officials believe they can handle what they expect to be a surge in customers — especially those who play table games — over the busy weekend, which they kicked off with a champagne toast on the casino floor as the restrictions expired at midnight. “The requirements that go with being fully compliant with the COVID restrictions are a lot,” said Jenny Holaday, Encore’s executive vice president of operations. “Having those guard rails be removed is really exciting both for our employees and for our guests, so everybody can just relax and enjoy themselves and have a nice time.” Paul Sacco, CEO of the Massachusetts Lodging Association, said the summer is already looking “far better than last year.” “It really is the weekend of the change,” Sacco said. “After a year of agony.” Those venturing out this weekend will likely notice a difference — even amid the expected cool and damp weather....." 

They have been telling us it is hotter than ever, but here’s what to know as the street is full of hustle and bustle now that the state has eased COVID-19 restrictions.


What do you do if the kid doesn't, slap him and blame it on being up too late?


I certainly know the feeling of starting the whole schlep over, but I follow the early-to-bed, early-to-rise axiom so I can share life with the nature that offers me a fabulous bounty each and every day, thank God, and the Globe $cribes can all take the express elevator down where I will be there to greet them -- although probably not for the want! The opening of the pearly Gates will be the final disappointment.

{@@##$$%%^^&&}

Okay, I'm getting a little full of myself and that a sin so..... let's steel ourself and open the Gates of Hell:


Vivian Yee of the New York Times says the Iranian voters were in a pessimistic mood and the race has been marked, more than anything else, by a lack of interest.

I had a bit more interest in this:

"Voting bill showdown looms as GOP rejects Manchin plan" by Brian Slodysko and Christina A. Cassidy Associated Press, June 18, 2021

WASHINGTON — The Senate is set for a key vote Tuesday on a sweeping rewrite of voting and election law, setting up a dramatic test of Democratic unity on a top priority that Republicans are vowing to block.

Democrats appeared to be coalescing Thursday around changes to the bill that could win the support of moderate West Virginia Senator Joe Manchin, the lone Democratic holdout on the legislation, yet they still faced lockstep Republican opposition that will likely leave Democrats back where they started: lacking the votes to overcome a Republican filibuster. 

The bill, known as the For the People Act, has been touted as Democrats’ answer to a state-level GOP push to enact voting restrictions following the 2020 election. It passed the House in March, but has bogged down in the Senate as Democrats have debated among themselves — with Manchin ultimately declaring he couldn’t vote for it because it lacked bipartisan support, yet Manchin’s position has evolved and compromise appeared to be nearing after he proposed a series of changes this week to narrow its scope. His proposal received a boost Thursday when Stacey Abrams, a former Georgia gubernatorial candidate who is a leading Democratic voice on voting rights, said she “absolutely” supported it.

[She did a flip-flop but it is racist and sexist to call it out]

Still, in a narrowly divided Senate where Democrats must count on Vice President Harris to cast tie-breaking votes, any compromise will likely be for naught unless changes are made to Senate filibuster rules, which Manchin and others oppose. For now, it takes 60 votes to overcome a filibuster and advance legislation.

Over a dozen Senate Republicans took turns at the microphone during a Thursday news conference to denounce the bill, which they view as a federal overreach into state and local elections.

Senate Minority Leader Mitch McConnell, Republican of Kentucky, predicted all Republicans would remain in lockstep opposition regardless of what changes are made. As written, the Democrats’ bill would bring about the largest overhaul of US voting in a generation, touching nearly every aspect of the electoral process. It would blunt laws erected in the name of election security, like voter ID requirements, while curtailing the influence of big money in politics. It would create a nonpartisan process for redrawing congressional districts, expand mail voting and early voting, restore the rights of felons to cast a ballot, and scores of other provisions.

[The bill to ensconce never-ending national fraud is laughable on it$ face]

Manchin’s counter-offer, which is intended to entice GOP support, would leave significant portions of the sprawling bill intact, while curtailing, rewriting, or eliminating other key parts. What will ultimately come to the floor for a vote Tuesday remains unclear. Also not certain: whether Manchin will vote for it.

A national voter ID requirement favored by Manchin has emerged as one sticking point with some Democrats.

Manchin’s proposal is far softer than the strict photo ID requirements adopted by some states. It would require all states to check ID, but various documents including a utility bill could be used instead of a photo ID, a requirement already adopted by 15 states including Manchin’s West Virginia.

“That is what we’re negotiating,” said Minnesota Senator Amy Klobuchar, who is playing a lead role in guiding the legislation.

“We might squabble about one or two things,” said Senator Raphael Warnock, of Georgia, “but I am not about to sacrifice the good in the pursuit of the perfect.”

[Those are Pelosi's words coming out of his seat-stealing mouth]


Polls have shown notable bipartisan support for voter ID requirements -- meaning the American public does indeed care about fair elections and what was once the sacred right to vote -- and I have, unfortunately, lost a lot of interest in politics after both parties have thrown in with the CVD fraud.

There are some good leaders out there who are profiles in courage, but they are few and far between.

{@@##$$%%^^&&}

This here is the antithesis of it:

"President Biden urged unvaccinated Americans to get vaccinated, warning that a highly transmissible variant of the coronavirus could cause more deaths. “Even while we are making incredible progress, it remains a serious and deadly threat,” Biden said Friday during a White House event to celebrate 300 million doses of vaccine administered during the first 150 days of his administration. “The data is clear: If you are unvaccinated, you’re at risk of getting seriously ill, or dying, or spreading it.” Rochelle Walensky, the director of the Centers for Disease Control and Prevention, expects the Delta variant first detected in India to be the most prevalent strain in the United States in the coming summer months. COVID-19 cases have plunged in the country in step with vaccinations, prompting many people to resume pre-pandemic activities like indoor dining, sporting events, concerts, and travel in recent weeks, but a large swath of Americans — particularly in the politically conservative South — have declined shots despite warnings from health authorities that the virus remains a threat. “The Delta variant can cause more people to die in areas where people have not been vaccinated,” Biden said Friday. “Where people have gotten the two shots, the Delta variant is highly unlikely to result in anything,” he said, adding that “the existing vaccines are very effective.”

That came from Bloomberg and WaShington Compo$t, who recommended a trip up to Canada:

"Canada said Friday that it would extend restrictions on nonessential travel at the US-Canada land border until July 21, a move poised to further stoke frustration among the lawmakers, business groups, and residents on both sides of the border who have been pressing Ottawa to begin lifting them. The restrictions, which have been in place since March 2020, have had limited impacts on trade and commerce, but they’ve split apart families, disrupted life in tightly knit border communities, and badly hurt the tourism industry in Canada, which is reliant on American visitors during the summer season. Canadian officials have suggested that the reopening of the border will happen in phases. Prime Minister Justin Trudeau has said that he wants 75 percent of Canadians to have a first dose of a coronavirus vaccine and at least 20 percent of them to be fully vaccinated before easing the measures. As of June 17, nearly 66 percent of Canadians had received at least one dose, while roughly 16 percent have been fully vaccinated. Canada had been extending the interval between doses to get some protection to more people more quickly amid what were initially limited supplies. “We’re not out of this pandemic yet,” Trudeau said. As vaccination rates in Canada have risen, calls have mounted for the country to begin easing some of the measures, and several US lawmakers from across the political spectrum have pushed President Biden to lift the measures unilaterally." 

That criminal tyrant has turned Canada into a hellhole, and my sympathies go out to those up north although I know we are all in the same boat and.....


".... they'll be shutting it all down again in the fall...for the Kill...that's when they're going to blame the mass deaths of the vaccinated on "variants" and the "unvaccinated" and then they're going to round us all up to drag us off to gulags...and here's the kicker....." -- Greencrow


I highly suggest you click on that link and read the rest of the post as well as run the blog roll as I do everyday (not because I'm on it), and I can not help but agree with her because it has been planned for a long time and nothing other than divine intervention will cause them to deviate save a mass awakening amongst the world's populace.

The New York Times says book a trip to Europe instead -- as long as you have had your $hot, of cour$e:

"When Johnson & Johnson’s single-dose coronavirus vaccine was authorized for emergency use in the United States in late February, it was seen as a breakthrough for reaching vulnerable and isolated Americans, a crucial alternative to vaccines that require two shots weeks apart and fussier storage. It was soon popular on college campuses, in door-to-door campaigns, and with harder-to-reach communities that often struggle with access to health care, but with only 11.8 million doses administered in the United States so far — less than 4 percent of the total — the “one and done” vaccine has fallen flat. States have warned that they may not find recipients for millions of doses that will soon expire, partly because the vaccine’s appeal dropped after it was linked to a rare but serious blood-clotting disorder and injections were paused for 10 days in April. The vaccine took another hit last week, when regulators told Johnson & Johnson that it should throw out tens of millions of additional doses produced at a plant in Baltimore because they might be contaminated. Although millions of Americans have yet to be inoculated, the vaccine’s role in the United States is fading fast. Experts lament a missed opportunity to address health disparities with a shot that should have been ideal for reaching vulnerable populations." 

That's about as close as they get to mention the tens, if not hundreds, of thousands of deaths and adverse reactions piling up across the planet.

All $afe and highly effective, blah, blah.

{@@##$$%%^^&&}

That's one reason I'm sick of the $elf-$erving, war-mongering whining:


The AmeriKan pre$$ must be jealou$!


My initial reaction was how after they swept national elections last month?


Sadly, I have lost interest in agenda-advancing UN propaganda from the mouthpiece pre$$.

{@@##$$%%^^&&}

Forgot all about the children:


"Children and other relatives of Biden aides get administration jobs" by Sean Sullivan and Michael Scherer Washington Post, June 18, 2021

WASHINGTON — Barely a week into office, President Biden made a promise that signaled a sharp break from his predecessor: No member of his family would be involved in government, but that vow did not extend to his senior staff and their relatives. In the first few months of Biden’s presidency, at least five children of his top aides have secured coveted jobs in the new administration. They include two sons and a daughter of the White House counselor, the daughter of a deputy White House chief of staff, and the daughter of the director of presidential personnel.

The pattern continued this week. “While it may not be as bad as appointing your son or daughter to a top government post as Trump did with Jared and Ivanka, it is still bad,” said Walter Shaub, who served as director of the Office of Government Ethics from 2013-17. “‘Not as bad as Trump’ cannot be the new standard.”

Trump’s daughter Ivanka Trump and her husband Jared Kushner worked in the White House as unpaid senior advisers, moves that outraged ethics experts, even as a Justice Department opinion found the president has special hiring authorities. Some relatives of top Trump officials and aides also were hired into the administration.

Beyond children, other relatives of top Biden aides also have secured high-level administration jobs or nominations. They include the wife of White House Chief of Staff Ron Klain and the sister of White House press secretary Jen Psaki.

Federal law generally prohibits government officials from hiring close relatives or encouraging their hiring, and there is no evidence that any of Biden’s aides have played a role in securing the jobs for their children or other relatives.

The White House has maintained that everyone hired has been well-qualified for their positions.

“The president has instituted the highest ethical standards of anyone to ever hold this office,” deputy White House press secretary Andrew Bates said, “and he’s proud to have staffed the most diverse administration in American history with well-qualified public servants who reflect his values,” but the hiring of senior aides’ children remains alarming to ethics experts, because it suggests that people with ties to high-ranking public servants might be getting an advantage over similarly qualified people for low-ranking positions, which often serve as a foot in the door to a career in government and politics.....

[Blog editor's head exploded]


Related:

"The White House reiterated President Joe Biden’s opposition to indexing the gasoline tax to inflation to help pay for an infrastructure plan, raising new questions about the viability of a bipartisan compromise emerging in the Senate. “After the extraordinarily hard times that ordinary Americans endured in 2020 -- job losses, shrinking incomes, squeezed budgets -- he is simply not going to allow Congress to raise taxes on those who suffered the most,” White House spokesman Andrew Bates said in a statement. A bipartisan group of 21 senators has been working to finish a $579 billion infrastructure proposal to counter a $2.25 trillion plan that Biden initially proposed. A draft outline of the lawmakers’ plan obtained by Bloomberg lists several funding sources that have been opposed by the White House. House Speaker Nancy Pelosi also has shot down the idea, dashing prospects House Democrats would go along....."

Is she the real president right now?


{@@##$$%%^^&&}


The Globe put a Hood over that Bliss-ful article by placing it on the back page.


{@@##$$%%^^&&}


He also worked at the YMCA!

Time to bury that under a sheet of paper:


Stella!

I coulda been a contender. Instead, I'm just a bum!


I didn't even bother to take a bite and left it for you if interested.

{@@##$$%%^^&&}


He claims the job killed him.

His lack of response led to this:

"A woman was injured when she jumped from a second-story balcony Thursday night to escape a massive blaze that destroyed a Cape-style home on Baboosic Lake, fire officials said. Two firefighters were also injured in the fire that broke out shortly before 7 p.m. at 2 Shore Drive Extension. Crews arrived to find heavy smoke and flames and a second-alarm was immediately struck, drawing crews from several surrounding communities, the department said in a statement. The woman who jumped from the balcony was rescued by a passing boater, who took her to an ambulance waiting on shore, which took her to a hospital, the statement said. Her condition was not known. Two firefighters suffered minor injuries and had been released from the hospital by Friday morning, Fire Chief Matthew Duke said. By 11 p.m., the fire was mostly out, but the home was on the verge of collapsing. A backhoe from the town’s public works department arrived to tear down the house, allowing firefighters to continue fighting the fire in hard-to -each areas, Duke said. The cause of the fire remains under investigation."

They then took a ride around the neighborhood:

"A 36-year-old Palmer woman died and a juvenile was seriously injured in a rollover crash on the Massachusetts Turnpike Friday afternoon, according to State Police. The woman was driving a 2005 Subaru Forester eastbound when she lost control, causing the vehicle to roll over and cross into the westbound lane at 1:45 p.m., State Police said in a statement. No other vehicles were involved in the crash. Witnesses and emergency personnel attempted to perform life-saving measures on the woman, but she died of her injuries, State Police said. The juvenile was taken to Baystate Hospital with serious injuries. The cause of the crash is under investigation, State Police said."

"A 1-year-old child was seriously injured in a two-car crash on Route 24 south around 9:40 p.m. Thursday, State Police said. The child was taken to Boston Children’s Hospital. The condition was not known Friday. The child was riding in a Toyota Sienna van driven by a 28-year-old woman from Fall River, State Police said in a statement. The child was riding along with a 3-year-old and a 40-year-old man from Fall River when the car changed lanes due to road construction, the statement said. At the same time, a Volvo S60 sedan driven by a 17-year-old from Taunton was traveling on the highway and it rear-ended the van, “causing both vehicles to spin out of control,” the statement said. The 1-year-old suffered the most serious injuries. The driver and other passengers in the van were taken to Good Samaritan Hospital in Brockton for treatment of minor injuries. The Volvo driver was taken to Morton Hospital for treatment of minor injuries, State Police said. The crash remains under investigation."

"Police are looking for a man believed to be in his 30s or 40s who they say asked a 13-year-old girl to get into his car as she walked back from a neighbor’s house Tuesday. He is described as a white male, with dark eyes and a wide jaw “and looking as if he works out,” police said. The teen was headed home around 6:05 p.m. when the man allegedly stopped and asked her if she wanted to get in his vehicle, a small black sedan, according to police. The girl immediately returned to her friend’s home and the man left the area. On Friday, police were able to obtain an image of the car they believe the man was driving, Police Chief Sean Gibbons said. Anyone with information is asked to contact Wayland Police....."

"Residents can rest easy knowing the culprit behind a series of vehicle break-ins has been identified on video as a bear. The black bear has been spotted in the town over the past few weeks, just as residents began reporting to police that their vehicles had been broken into, Police Chief Ken Miller said. Police believe the bear is looking for food, and they are urging residents to remove food items from their vehicles and not to leave trash outside. In several instances, the bear has climbed into a vehicle’s trunk or the bed of a truck to try and get a bite to eat."

He saw to Japan before they found him:

In this image made from a video, a brown bear runs on a field in Sapporo, northern Japan Friday, June 18, 2021. The wild brown bear on the loose all night in the city wounded four people, entered a military camp and disrupted flights at the airport Friday before being shot and killed by authorities. (NTV via AP)
In this image made from a video, a brown bear runs on a field in Sapporo, northern Japan Friday, June 18, 2021. The wild brown bear on the loose all night in the city wounded four people, entered a military camp and disrupted flights at the airport Friday before being shot and killed by authorities (NTV via AP)."

The sad thing is the misanthropic Globe gave the death of a baby swan more ink than a person.

Also see:

"In 1865, Union troops arrived in Galveston, Texas, with news that the Civil War was over, and that all remaining slaves in Texas were free — an event celebrated to this day as “Juneteenth.”

In 1953, Julius Rosenberg, 35, and his wife, Ethel, 37, convicted of conspiring to pass US atomic secrets to the Soviet Union, were executed at Sing Sing Prison in Ossining, N.Y.

The truth that he was, in fact, a spy came to light after the collapse of the Soviet Union

In 1975, former Chicago organized crime boss Sam Giancana was shot to death in the basement of his home in Oak Park, Ill.; the killing has never been solved.

That was just before he was slated to testify to the House committee investigating the death of JFK.

In 2011, Libya’s government said NATO warplanes had struck a residential neighborhood in the capital and killed nine civilians, including two children; NATO confirmed hours later that one of its airstrikes had gone astray.

Looks like a war crime to me, based on lies from Obama and the pre$$.

{@@##$$%%^^&&}


Related:

"Wilmington schools suspend staffer after DCF supports abuse allegation; middle school staffer now under investigation" by John R. Ellement Globe Staff, June 17, 2021

The state’s child protection agency is investigating an allegation that a middle school staffer in the Wilmington public schools abused at least one student, which comes after another staffer was placed on leave for allegedly abusing a special needs student in an early childhood center.

In a letter to parents Wednesday, Wilmington Schools Superintendent Glenn Brand wrote that the Department of Children and Families had sustained allegations that a staffer at the Wildwood Early Childhood Center had abused or neglected at least one child. The center offers pre-kindergarten and kindergarten classes in 11 classrooms, according to state records and Wilmington Schools.

“We placed the staff in question on administrative leave as soon as we were made aware of those claims,” Brand wrote, adding that an outside investigator has been hired to examine the circumstances at Wildwood. “We recently learned from DCF that some of the claims have been supported.”

Now, the issue has expanded to a separate school and facility — the town’s middle school, which serves grades six through eight.

“Last week, we became aware of a separate series of allegations of misconduct by a staff member at Wilmington Middle School,” Brand wrote. “That staff member has also been placed on administrative leave pending a DCF investigation.”

Brand did not identify the jobs held by the persons under DCF investigation. “Out of respect for all those involved and based on legal requirements, we are not able to discuss the specifics of these cases,” he wrote.....


You don't want the kids in their hands.

{@@##$$%%^^&&}


{@@##$$%%^^&&}


Some progressive groups and activists demanded that the nonprofit organization give money directly to victims of shootings instead.

{@@##$$%%^^&&}

Nothing personal, just bu$ine$$:


Yeah, the banks are going to solve the wealth gap. 

That's like hiring the fox for $ecurity at the henhou$e after OneUnited failed to payback bailout loot and has connections to their Congre$$ional over$eer Maxine Waters.


They want to pack us into the high-rises like $ardines.

Now let's eat!

"Massachusetts employers added 9,200 jobs in May, state labor officials said Friday, a smaller gain compared to the month prior and a sign that businesses are still struggling to find workers as the state reopens. The speed of job recovery in Massachusetts, which lifted nearly all coronavirus restrictions on May 29, trails national figures. The state’s unemployment rate dipped to 6.1 percent last month compared to a revised rate of 6.4 percent in April. Although the jobless rate is trending downward, that number is higher than the national average, which fell to 5.8 percent last month, according to the Bureau of Labor Statistics. Employers have been scrambling to hire workers in recent weeks to keep up with the reopening and accommodate pent-up demand from consumers. Despite indications that the economy is rebounding, the Labor Department reported Thursday that new claims for unemployment benefits ticked upward last week, following several weeks of declines....."

Sorry, I'm $ick of eating Globe $lop.

{@@##$$%%^^&&}


The only thing left to talk about was the ad for golf wear given his appearance on the flight manifest.

Yeah, it's the end of an era, and you saw who else made the list.

Oh, what I wouldn't give for a honorable and Honest actor:

"The Honest Co. made its trading debut Wednesday in a further test of cofounder Jessica Alba’s pitch to would-be wellness investors. The personal-care products brand and its venture capital backers raised $413 million in an initial public offering Tuesday, selling 25.8 million shares for $16 each after marketing them for $14 to $17. An actress turned entrepreneur, Alba included a letter to potential investors in the company’s filings touting Honest Co.’s commitment to healthy products. In addition to baby products like shampoos, the company also sells cosmetics as well as cleaning supplies, a collection that was launched during the coronavirus pandemic."

Did you happen to see the outfit she was wearing?

Sunday, June 20, 2021

May Flower: Time to Ginkgo

They want to genetically modify more than just the crops as "gene therapy" is meant to be ubiquitous and never-ending going forward, cui bono?

That's where the p$ychopaths who stole all the money are pu$hing things if the pre$$ $poke$people are to be believed, in what will no doubt be a horrific anti-human being dy$topia and Borg collective circling us all.

It's an octopus that is hard to get a hold of as it buys up all the property as part of the Great Communi$t Re$et, for lack of a better term.

"Ginkgo plans a $17.5 billion merger with SPAC that took DraftKings public" by Jonathan Saltzman and Anissa Gardizy Globe Staff, May 11, 2021

Ginkgo Bioworks, one of the hottest biotech startups in Massachusetts, said Tuesday that it plans to go public through a $17.5 billion merger with a so-called blank check company backed by Harry Sloan and Jeff Sagansky, the veteran media industry executives who helped take the Boston sports-betting company DraftKings public last year.

The deal values Ginkgo at $15 billion, making the merger one of the biggest of its kind. Ginkgo programs cells to produce new proteins, scents, antibiotics, cannabinoids, and other products for a growing array of industries. Launched in 2008 by five scientists from the Massachusetts Institute of Technology, it now employs about 500 people, most of them in Boston’s Seaport.

[That is one hell of a blank check]

The merger with Soaring Eagle Acquisition, a special purpose acquisition company, or SPAC, is expected to fetch $2.5 billion for the combined entity, according to Ginkgo. A SPAC is a shell corporation listed on a stock exchange for the purpose of acquiring a private company, thus taking it public without all the paperwork of a traditional initial public offering.

[The $tock market is literally a $hell game to enrich the u$ual $u$pects, with devastating results for the rest of us]

Jason Kelly, Ginkgo’s cofounder and chief executive, said his firm was attractive because the world has seen the extraordinary potential of engineered biology, from the groundbreaking messenger RNA coronavirus vaccines made by Pfizer-BioNTech and Moderna to tasty animal-free proteins used in the latest generation of meatless burgers.

[Straight out of the damn WEF playbook!]

“From mRNA vaccines reaching people’s arms to combating climate change, the opportunity to work with programmed cells has never been more apparent,” he said. “Ginkgo’s platform makes it easier to program this code, and we are making this platform available to organizations working to solve our most pressing problems.”

[See how they roll the whole damn agenda together when the two have nothing to do with each other -- apart from climate change and CVD being total frauds and ma$$ive lies?]

Ginkgo has cut several multimillion-dollar deals in recent years, including one with Toronto-based Cronos Group for $122 million to produce cultured cannabinoids, another with the Swiss drug giant Roche that’s worth up to $160 million to discover novel antibiotics, and another with Cambridge-based Synlogic, in which Ginkgo invested $80 million to speed the development of living medicines. During the pandemic, Ginkgo created Concentric by Ginkgo, a COVID-19 testing program to help schools and businesses reopen.

[Well, that sure bends the joint you may be smoking.

One need not be stoned to see through the haze of the $elf-inflicted cri$i$ for ulterior and nefarious motives at this stage.

The smoke has cleared away and we can see]

Under the merger announced Tuesday, a number of investors have pledged $775 million, including Baillie Gifford, Putnam Investments, and accounts managed by Counterpoint Global.

Soaring Eagle, the blank check company that will merge with Ginkgo, was founded last year by former Hollywood executives Sloan, Sagansky, and Eli Baker of Eagle Equity Partners. They helped take DraftKings public last year in another SPAC merger. SPACs have long existed on the fringes of the financial world but have surged in popularity in the last year or two.

Although science and gambling would appear to have few things in common, Sloan said in a conference call Tuesday that he is attracted to companies like DraftKings and Ginkgo because they are in a “category of one.”

“These are companies that are not only leaders in their field but actually created the field themselves,” he said. “That is certainly the case with Ginkgo and synthetic biology.”

[How do you feel about your health care being in their hand$?

Makes me $ick]

He said he learned about Ginkgo from a Soaring Eagle board member who works with Arie Belldegrun, a cell- and gene-therapy veteran and founder of Kite Pharma and Allogene Therapeutics, who saw Ginkgo’s potential to merge with a blank check company.

“It was Arie’s very deep knowledge in life science and his excitement about Ginkgo which caused us to decide to partner,” Sloan said.

Belldegrun and Soaring Eagle are cosponsoring the $1.73 billion SPAC investment and participating in a private investment round with other investors.

Kelly said during the conference call that he spoke with several SPACs about a possible merger, but viewed Belldegrun’s involvement with Ginkgo as a big plus, given the latter’s background in drug making. Both Sloan and Belldegrun will join Ginkgo’s board of directors.

“If you want to do the large, commercial partnerships that we do with pharma companies, you need breakthrough technology, and you also need credibility with that community,” said Kelly, who will lead the combined company.

Ginkgo makes money two ways, according to Kelly. It charges companies for research and development that it does in its foundry, and it licenses those findings, or the code it has written, back to the customer in exchange for royalties on the sale of a product or an equity stake in the firm.

Last year, Ginkgo generated $64 million in revenue from research and development, Kelly said, and it expects that number to top $1 billion in 2025. Ginkgo has worked on 54 programs since 2017. In 2025, Kelly said, Ginkgo expects to start more than 500 new programs.

Ginkgo was one of the first life-sciences companies to put down roots in the Seaport. It occupies about 200,000 square feet of research and cell-design facilities, some of it in the Innovation and Design Building. In April, it announced that it had agreed to lease an additional 150,000 square feet across the street in an eight-story lab building proposed by Marcus Partners, along Fid Kennedy Avenue in the Raymond L. Flynn Marine Industrial Park. Work on the building, which needs city approval, would start next year and be completed in 2024.

Ginkgo also occupies more than 63,000 square feet in two buildings in Cambridge, where it expects to have about 70 employees by the end of May, according to a spokesman.



"Marc Archambault is well aware of the controversy surrounding Biogen’s new drug for Alzheimer’s disease, including that three members of a scientific advisory committee to the Food and Drug Administration quit in protest last week after the agency approved it over the panel’s objections. Still, he was thrilled to roll up the left sleeve of his blue button-down shirt Wednesday at Butler Hospital in Providence to receive one of the first intravenous infusions of the drug, Aduhelm, since its June 7 approval. He wasn’t concerned that many in the scientific community say evidence that it works is thin. “I’m comfortable with it a hundred percent, and whatever happens, happens,” said Archambault, 70, a real estate broker in South Kingstown, R.I. “I think it’s going to be great, and I wanted to be part of it.” He also appeared to question the empathy of the three physician scientists who quit the advisory committee that overwhelmingly recommended in November that the FDA reject the drug in light of contradictory results in two large clinical trials....."

The courageous truth tellers have been scorned throughout history, so why should now be any different?

One can get depressed when one realizes how easy it is to win FDA approval for things that don't work but are harmful.

Related:

"A Mass. software engineer’s bot helped people find vaccine appointments. Now he’s shut it down, and the thank-yous are rolling in" by Martin Finucane Globe Staff, June 10, 2021

A Massachusetts software developer’s Twitter bot offered help to those seeking vaccine appointments at a time they were frustratingly scarce. Now he’s shut it down, and hundreds of people are saying thank you.

Developer Dan Cahoon tweeted on Wednesday, “With vaccines now readily available in Massachusetts I’m going to turn off vaccinetime,” and he referred people to the state’s website.

The tweet garnered more than 230 replies by midafternoon Thursday, with many saying they had used the bot to get not only themselves but others vaccinated. The replies reflected the tense times the state saw when vaccines were first made available but there wasn’t enough supply to meet the demand.

“It’s really great to see how many people it was able to help,” said Cahoon, a software developer at Ginkgo Bioworks. He said he developed the bot in his spare time after watching colleagues struggle to find appointments on the multiple websites where they were listed.

While media outlets earlier this year included bots in their lists of tips on how to get a vaccine appointment, some critics have said they gave the tech-savvy an advantage. Cahoon said he felt his bot leveled the playing field between people who only had limited time to search for appointments and people who had the time to sit at the screen for hours clicking away.

“Hopefully, it brought a little more fairness to the system,” Cahoon said. He also said that if the unthinkable happens and there’s another pandemic, it would be better if there was a single website people could go to and preregister.

After enduring the early frustrations, the state is now a national leader in vaccinations.

The safe and effective vaccines are free for people who live, work, or study in the state. People 12 to 17 can receive the Pfizer vaccine. People 18 and older can receive either the Pfizer, Moderna, or Johnson & Johnson vaccine, the state says.....


Time to $pin off to $omething new:

"Ginkgo’s spinout Motif to release plant-based meat tech after raising $226 million" by Anissa Gardizy Globe Staff, June 16, 2021

The plant-based food startup that spun out of Ginkgo Bioworks is getting ready to unveil its first product.

Boston’s Motif FoodWorks, with $226 million in new funding, announced on Wednesday that it plans to release food technology designed to improve the taste and aroma of meat alternatives by the end of the year. Another product designed to add texture and juiciness to fake meat is expected to be available next year.

The developments come more than two years after Ginkgo started Motif to break out its food business, inspired by the successes of other companies like Impossible Foods, which uses science to mimic the attributes of animal meat with its Impossible Burger.

[This is an abomination and remember this when the planned and forced famines hit.

The population has no idea, just like 100 years ago, but the genocide is being waged on a global scale this time with the benefit of poisonous gene therapies called vaccines

I know it is tough to choke down, but there it is]

The difference with Motif is that instead of releasing its own line of foods, it plans to partner with companies that may not want to develop the tech behind plant-based food on their own. A Motif spokesperson said that in many cases, a consumer packaged goods company would include Motif’s technology in a plant-based product it plans to sell in retail settings.

“Plant-based foods have the potential to unlock enormous benefits for people and the planet, but that will only happen if they live up to, or even exceed, what consumers expect from animal-based counterparts,” said Jonathan McIntyre, the chief executive of Motif, in a press release.

[Enjoy your nutritious gruel from the lord of the manor]

Motif’s website indicates that it is also working on improving the stretchiness of plant-based cheese and the creaminess of dairy alternatives. The new funding, which brings Motif’s total haul to $345 million, will allow the company to add at least 50 people to its 35-person team by the end of the year.

The food startup is located in a 10,000-square-foot space in the same building as Ginkgo in the Seaport District. Ginkgo announced last month that it plans to go public through a $17.5 billion merger with a SPAC, or special purpose acquisition company.

The Motif funding round was led by Ontario Teachers’ Pension Plan Board, through its investment arm that backs growing technology companies, and funds and accounts managed by BlackRock. Additional new and previous investors also participated in the round.

[Nothing wrong with any of that, right? 

It's all good?]


How do you like their logo?

Time to cannibalize the rest.

{@@##$$%%^^&&}

"Waltham biotech raises $110 million for gene therapy treatments" by Jonathan Saltzman Globe Staff, May 3, 2021

Affinia Therapeutics, a Waltham-based biotech working on gene therapies to treat diseases using technology developed at Massachusetts Eye and Ear, said Monday it has raised $110 million in a new venture capital round.

[The venture capital money comes from pension funds and college endowments as well as private equity, so the ba$ic effect is funding our own demise at the hands of these mon$ters]

The company, which was founded in 2019 based on work pioneered by Luk Vandenberghe, an associate professor at Mass. Eye and Ear and Harvard Medical School, plans to use the money to advance its gene therapy technology and move experimental drug programs into clinical trials.

Gene therapies are among the most promising, if technologically challenging, areas of medicine. By engineering a virus to carry functioning genes to cells to compensate for defective ones, drug makers have developed several revolutionary treatments for devastating genetic diseases, from a rare neurodegenerative disorder to a form of blindness.

[You can see where the "viru$" come from now, right?

It's in the "vaxxeens"]

The one-time treatments can be breathtakingly expensive, with price tags of $1 million or more. Proponents, however, say such expensive medicines may actually be cost-effective by curing debilitating diseases that strain the health care system if treated for years with conventional drugs and hospitalizations.

The $110 million raised by Affinia supplements $60 million in financing that the firm announced in March of last year. The latest round was led by EcoR1 Capital and Farallon Capital Management, both based in San Francisco.

Additional new investors include Avidity Partners, Casdin Capital, GV, Octagon Capital, Perceptive Advisors, RA Capital Management, TCG Crossover, and Woodline Partners LP. Previous investors Atlas Venture, F-Prime Capital, Lonza, Mass General Brigham Ventures, and New Enterprise Associates also participated in the round.


I'm losing my Affinia for the Globe by the minute.

{@@##$$%%^^&&}

In the past, inoculations have given people cancer, and that's all I'm going to say on that:

"Cambridge cancer drug startup Nuvalent raises $135 million; The new funding comes just four months after it was launched with $50 million" by Jonathan Saltzman Globe Staff, May 11, 2021

Nuvalent, a Cambridge biotech working on precision cancer drugs, has raised another $135 million in venture capital just four months after the firm was launched with $50 million in financing.

The startup is developing lung cancer drugs that rely on enzyme blockers known as kinase inhibitors to help keep cancer cells from growing. Nuvalent hopes to use cash from the second round of financing to advance two potential drugs into clinical trials.

Nuvalent also recently announced the appointment of Dr. Christopher Turner, an oncology expert and former vice president of clinical development at Cambridge-based Blueprint Medicines, as chief medical officer.

“The milestones that we announced today support our significant achievements since our public launch in January 2021 and the tremendous potential that we believe Nuvalent has,” said James Porter, the company’s chief executive.

The technology behind Nuvalent’s scientific approach was developed with guidance from Matthew Shair, a professor of chemistry and chemical biology at Harvard University. He serves as founder, head scientific adviser, and a member of the board of directors.

The latest financing round was led by Bain Capital Life Sciences with participation from the founding investor Deerfield Management, and 10 new investors, including Fidelity Management and Research Company, Wellington Management Company, and Viking Global Investors. Dr. Andrew Hack, a managing director at Bain, will join Nuvalent’s board of directors.

[What a $hock!]


Related:

"Verve Therapeutics, a Cambridge biotech startup that wants to use gene editing to lower cholesterol and reduce the risk of heart disease, made a successful stock market debut Thursday, with its share price surging more than 60 percent. Verve shares closed at $31.92, up 68 percent from the initial $19 offering. That offering was itself above the price of $16 to $18 that Verve had previously set. The stock is trading on the Nasdaq under the ticker symbol VERV. Verve sold more than 14 million shares in its IPO, raising nearly $267 million from investors enthusiastic about its novel approach to treating cardiovascular disease with the genome-editing tool CRISPR. The company wants to make gene-editing medicines that mimic genetic mutations that naturally prevent some people from developing high levels of LDL, or “bad,” cholesterol, or high levels of triglycerides, or both....."

Oh, the Verve as the Globe tours the labs.

{@@##$$%%^^&&}

Can you $ee yet?

"Atlas launches second Cambridge biotech to tackle vision loss; The new company has raised $77 million in venture capital" by Jonathan Saltzman Globe Staff, May 18, 2021

Call it “Quest for Sight: The Sequel.”

In September, the Swiss drug giant Novartis paid $150 million for a Cambridge startup that had developed a pair of potential gene therapies to restore vision to people with blindness stemming from genetic diseases. It was a sizable return for the biotech, which had used roughly half of the $21 million in venture capital it had raised after its founding about 17 months earlier by Atlas Venture.

Now the same research and leadership team behind Vedere Bio has launched Vedere Bio II, a second Cambridge biotech working on other experimental gene therapies for vision loss, including retinitis pigmentosa and age-related macular degeneration. The new company has raised $77 million in venture capital and is headed by the same chief executive, who said he’s not thinking about a sale to another pharma giant ― at least not yet.....


Related:

"Lexington biotech licenses experimental cancer drug to Bristol Myers Squibb for $200m; It’s the biggest such deal for Agenus since the company was founded in 1994" by Jonathan Saltzman Globe Staff, May 18, 2021

The Lexington-based biotech Agenus has licensed an experimental cancer-fighting drug to the pharmaceutical giant Bristol Myers Squibb for $200 million, the biotech’s largest licensing deal since it was founded in 1994.

[The shots are experimental as well for the lab rats they call sheeple]

Agenus, which works on medicines that harness the body’s immune system to treat cancer, said Tuesday that Bristol Myers Squibb will advance the development of an immuno-oncology drug that shows promise against tumors, including non-small cell lung cancer.

[I know a tumor I think should be cut out from the American body politic, but that's a different subject]

If the drug meets development, regulatory, and commercial milestones, Agenus could receive up to $1.36 billion more, under the agreement with New York-based Bristol Myers Squibb. Agenus has no approved drugs on the market.

[The same as modeRNA]

Debbie Law, a senior vice president for the multinational pharmaceutical giant, said Agenus’s experimental drug shows “potential for potent anti-tumor activity.”


Also $ee:

"Klaviyo, a marketing technology company based in Boston, said Tuesday it has raised $320 million. The new funding, which comes about six months after a $200 million round in November, doubles the company’s valuation by investors to more than $9 billion. Klaviyo helps businesses do their own marketing without forking over customer data to third-party platforms or marketplaces, said Andrew Białecki, a cofounder and the chief executive of the firm. Klaviyo provides companies with analytics tools to track and understand consumer behavior, while also offering channels for communication such as e-mail or text messaging. “We believe that at the end of the day, owning relationships with consumers will help businesses become closer to their customers, more durable, and more profitable,” Białecki said in a statement, “and that’s not only a better way of doing business — it’s the next era of digital relationships.” The funding round was led by Sands Capital, with participation from new investors including Counterpoint Global, Whale Rock Capital Management, ClearBridge Investments, and Keith Block, the former cochief executive of Salesforce. The company has raised more than $675 million to date....."

{@@##$$%%^^&&}

"Glaxo agrees to $2.1 billion cancer-therapy deal with iTeos" by Suzi Ring Bloomberg, June 14, 2021, 4:40 p.m.

GlaxoSmithKline will pay Cambridge-based iTeos Therapeutics as much as $2.1 billion to develop a potential immune therapy as the British drug maker rebuilds its pipeline of cancer drugs.

Glaxo and iTeos agreed to develop and commercialize the monoclonal antibody treatment, which is in early-stage trials against advanced solid tumors, they said in a statement Monday. ITeos will receive an upfront payment of $625 million, with additional milestone payments of up to $1.45 billion.

Shares of iTeos soared as much as 77 percent in trading before US markets opened. It ended the day up 37.29 percent, at $27.50.

Glaxo has been expanding in the lucrative field since Emma Walmsley took over as chief executive in 2017. The company, which had sold its cancer assets to Novartis in 2015, now has three oncology drugs on the market, with the therapy area making up about a quarter of its pipeline. The deal comes a week before a key investor day where Glaxo will detail plans to split in two, spinning off its consumer unit into a separate business.

The companies will also test the monoclonal antibody, known as EOS-448, next year in combination with Glaxo’s cancer drug Jemperli, which was approved in the United States and Europe in April for recurrent or advanced endometrial cancer. Glaxo and iTeos will share any profits from the tie-up in the United States.


{@@##$$%%^^&&}

Now for the Flag$hip of Bo$ton:

"Flagship Pioneering raises more cash for new biotech fund; The Cambridge venture capital giant, which spawned Moderna, now has $3.4 billion to spend on startups" by Anissa Gardizy Globe Staff June 14, 2021

As the pandemic was raging in April 2020, Flagship Pioneering raised $1.1 billion for its seventh fund focused on spawning the next wave of biotech startups.

Now, as the world begins to emerge from the pandemic — in part because of the COVID-19 vaccine from Moderna, one of Flagship’s companies — the Cambridge venture capital giant says it has more than tripled that amount.

[Then the drill is over?]

After raising additional funds, Flagship said Monday that it has $3.4 billion to spend on a generation of biotech companies focused on therapeutics, agriculture, and nutrition, and while drug makers typically concentrate on developing treatments for diseases, Flagship is building an internal division that will work on developing medicines for healthy people. These therapies would be intended to protect, maintain, or improve health so a person could better ward off infectious disease threats, as well as “existing pandemic diseases such as obesity, cancer, and neurodegeneration.”

“The pandemic has laid bare the critical nature of health, not only to individuals, but to economies and societies,” said Ara Darzi, who’s heading the initiative, in a press release.

[You $ick f**ks!

HEALTHY PEOPLE DO NOT NEED YOUR "medicine"]

The expanded funding comes as Flagship continues to support its existing companies and launch new ones. The firm poured $370 million into its startups over the last four quarters, and other investors kicked in $4.4 billion.

Flagship has spun out several biotechs over the last year, including Laronde, Generate, Invaio Sciences, and Valo Health, which announced last week that it was pursuing a SPAC merger. And Flagship startups, including Inari Agriculture, Indigo Ag, Tessera Therapeutics, and others, have raised $1.8 billion from private investors in the last year.

Since its founding in 2000, Flagship has created 41 companies.


Now you where a lot of the bailout loot went, too.

Also see:


It's “not a good look for the industry if the person who approved the vaccine went to work for an affiliated company,” but I've been told that the “COVID-19 pandemic brought into stark focus how important it is to bring increased attention and investment to our health security globally, and to preemptive medicine more broadly,” said Noubar Afeyan, the billionaire founder and chief executive of Flagship who also chairs Moderna’s board. Hahn is a radiation oncologist who served as chief medical executive at the MD Anderson Cancer Center in Houston before his appointment to the FDA. He said the pandemic has underscored how vital it is to invest in preventative medicine. Dr. Scott Gottlieb, who preceded Hahn as commissioner under Trump, joined the board of New York-based pharmaceutical giant Pfizer after leaving the government in 2019. Pfizer’s COVID-19 vaccine was the first cleared for emergency use by the FDA, on Dec. 11.the sign-off coming a week before Moderna received similar authorization. Earlier this month, Amy Abernethy stepped down as the FDA’s second-in-command to join Verily, the Google spinoff working on health care innovation. Another former FDA commissioner, Dr. Robert Califf, serves as an adviser to Verily. Several government watchdog groups criticized the trend on Tuesday, saying the appointment of former high-ranking FDA officials to leadership positions in biopharma erodes confidence in government regulation of the industry, but.....

{@@##$$%%^^&&}

"Innovation economy: Life sciences is poised to be Boston’s dominant industry. Has the area become the Silicon Valley of biotech?" by Scott Kirsner Globe Correspondent, June 15, 2021

The Boston area has long been famous for its elite universities, top tier hospitals, passionate sports fans, and deep history, but over the past year, the biggest buzz has been about biotechnology, from Moderna receiving emergency use authorization for its COVID-19 vaccine in December to Biogen winning approval for its Alzheimer’s drug last week.

There has also been a massive amount of investment, acquisitions, public offerings, and laboratory construction during a time when many businesses struggled to keep the lights on. The biotech sector seems poised to emerge from the pandemic as the city’s dominant and most visible industry. Might it finally be time to say that the Boston area has become the Silicon Valley of biotech?

“The concentration of capital, science, and people in Boston has never felt better,” says Bruce Booth of Atlas Venture, an investor who has worked in the city since 2005. Just this week, Flagship Pioneering, the company-creation factory in Cambridge that hatched Moderna, collected a fresh $3.4 billion in capital to keep funding new ventures.

In the stretch since December, you can find six major indications that Boston is the undisputed hub of the life sciences industry, a place where ideas and products that change ― and save ― people’s lives around the world originate.

All three COVID-19 vaccines approved for emergency use in the United States have ties to Boston. Moderna is headquartered in Cambridge’s Kendall Square. Much of the research underlying Johnson & Johnson’s single-shot vaccine was done at Beth Israel Deaconess Medical Center in Boston. And Pfizer has been relying on a production plant in Andover to produce millions of doses of its vaccine for domestic use, and for export to other countries as part of the Biden administration’s donation initiative.

Following approval from the Food and Drug Administration last week, Biogen is shipping the first doses of Aduhelm, its treatment for Alzheimer’s. The decision to approve the drug was contentious, as is its price — $56,000 a year, but no other company has been able to get an Alzheimer’s medicine on the market since 2003, a remarkable achievement for one of the linchpins of the state’s biotech industry.

British pharma giant AstraZeneca is paying $39 billion to acquire Alexion Pharmaceuticals, a publicly traded Boston biotech with about 3,800 employees that focuses on rare diseases affecting the kidneys, nervous system, and blood. That deal, expected to close this summer, will create a rare disease division within AstraZeneca that will be based in the Seaport District. Alexion came to town in 2017, relocating from New Haven Conn.

One of Alexion’s neighbors in the Seaport, Ginkgo Bioworks, is planning to go public this year, with a valuation of $15 billion. The company was founded in 2008 by a group of MIT alumni and a professor, Tom Knight. They were interested in building tools to more effectively manipulate DNA. The goal was to insert custom-crafted DNA into living organisms such as yeast or bacteria, to effectively hot-wire them to produce fragrances, chemicals, or key ingredients for animal feed. More recently, biopharma companies, including Moderna, Roche, and Bayer, have come to Ginkgo for its DNA engineering expertise and advanced facilities. Ginkgo added 150 jobs last year — its workforce is now about 500 people — and the company will eventually trade on the New York Stock Exchange under the ticker symbol DNA. Ginkgo also will be one of the largest SPAC offerings — the acronym stands for “special purpose acquisition company” — that the life sciences sector has seen.

[Yes, how wonderful!]

Construction of lab and office buildings intended for biotech tenants is zooming ahead. While many white collar industries may continue working remotely, biotech requires expensive gear for designing and testing its products, and the industry strongly believes in the benefits of in-person collaboration. Even Somerville, long considered terra incognita for biotech companies, is getting a 1.3 million-square-foot biotech campus. The first building at the Boynton Yards complex near Union Square will be finished this summer. All this development creates temporary construction jobs and permanent positions at companies, of course, but also boosts the local economy by increasing foot traffic for restaurants, shops, and other businesses.

[I would stay out of that $hithole, and the distancing isn't for them, huh?]

Eyebrow-raising venture capital and private equity activity has gone on unabated. It’s no longer unusual for biotech companies to raise half a billion bucks at the drop of a hat. Cambridge’s ElevateBio, focused on new cell and gene therapies, did it in March, and EQRx, working to develop more affordable cancer drugs, did it in January. All told, a record amount of capital flowed into the biotech sector during the first quarter of 2021: $12 billion, according to research firm PitchBook.

[While you were locked down they were con$tructing the Great Re$et with the loot they stole]

Importantly, these six examples are distinct from each other. “The fact that you can have such diverse significant events in such a short time is indeed perhaps evidence of the vibrancy of the ecosystem,” says Katrine Bosley, an executive who took the Cambridge gene editing startup Editas Medicine public in 2016 and now serves on several boards.

[They kind of talk makes me $ick]

From the outside, the industry can look like an exceptionally well-funded assembly line for pricey new treatments, but it never seems to create all that many jobs, and good luck breaking into the field if you’re coming from another industry. (The Massachusetts Biotech Council pegs industry employment in the state at 79,000, noting that it has added 24,000 jobs in the last decade. Still, that’s less than one Google.), but if the game we’re playing is capitalism — aiming to deliver returns for entrepreneurs, investors who take risks, and shareholders who go along for the ride — biotech is playing it with some laudable goals in mind, such as, keeping you alive (and healthier) longer. That mission has rarely been clearer than now, with vaccines designed or manufactured here diminishing the death toll from COVID-19, and now, maybe add to the list a new sense of tempered optimism for some of the estimated 6 million people suffering from Alzheimer’s in the United States.

[That is an absolutely disgusting paragraph as he advocates for their medical tyranny that is anything but life-saving. 

How evil do you have to be to put this out because I am astonishingly appalled by it]

How would we know, quantitatively, that we’ve become the undisputed heavyweight champ of the bio biz? One measure is that while the major pharmaceutical players are sprinkled around the world ― from Tokyo to Manhattan to Basel, Switzerland ― all 10 of the biggest pharma companies have a presence in Boston. Another is that when the trade publication Genetic Engineering & Biotechnology News published its annual list of the top US cities for biotech in April, the Boston-Cambridge cluster remained locked into the number one spot it’s held since 2015, when we took it from San Francisco. Massachusetts holds the top spot on other rankings as well, including the Milken Institute’s power rankings of state science and technology sectors.

Biotech investor Otello Stampacchia says the density of the local ecosystem — many key participants know one another and have collaborated over years and multiple jobs — has “contributed to making this a super-charged, faster-paced biotech hub.”

“The industry put its roots in the ground here over 40 years ago, but its growth spurt really began around 20 years ago,” says Michael Gilman, chief executive of Arrakis Therapeutics in Waltham, and a former Biogen research executive. “Since it takes 15 to 20 years to develop a drug, this is about when you’d expect it to flower.”


May it then quickly wilt, by God!

{@@##$$%%^^&&}

Time to cash out:

"The inventor of the World Wide Web is looking to cash in on one of the hottest trends in digital artworks. Tim Berners-Lee, who wrote the software underlying the Internet, is selling a computer file containing that original programming code plus a unique encryption signature as a form of collectible known as a nonfungible token, or NFT. The token will be sold at auction by Sotheby’s starting June 23 and running until June 30. Proceeds will benefit initiatives supported by Berners-Lee and his wife, the auction house said. Earlier this year, nonfungible tokens were among the hottest investments in the art world, culminating in March when auction house Christie’s sold an NFT linked to a digital work called “Everydays: The First 5000 Days” by the artist Beeple for over $69 million. NFTs, which rely on the same technology underlying digital currencies such as bitcoin and ethereum, have been created and sold, linked to everything from video clips of NBA players dunking to online cartoon cats, though the market has slumped somewhat since the Christie’s sale....."

Keep riding the wave until it cra$hes:

"Circle Internet Financial said it raised an additional $440 million, a huge cash infusion as the Boston company seeks to make it easier to use cryptocurrencies that are not subject to the massive swings in value common with Bitcoin and other leading digital coins. The private investment, announced late last week, comes as Circle has been working since 2018 on what is known as a “stablecoin.” Circle’s product is known as USDC, and it is linked to the price of the US dollar. The company’s funders include Boston’s Fidelity Investments, a longtime backer of cryptocurrency ventures, which earlier this year asked federal regulators for permission to launch a digital currency investment fund....."

Crypto is either a con or has been coopted, imho, because it leads to the digital currency that is part and parcel to the vaccination control program.

"Shares in Waltham med-tech firm PerkinElmer rose 6.85 percent Wednesday to close at $136.57 after the company raised its revenue and earnings guidance for the year. On Tuesday, after the markets closed, PerkinElmer told investors that it now expects revenue of $4.4 billion for the full year, compared to a previous estimate of $4.1 billion for 2021 and compared to $3.8 billion in 2020. Most of the growth is happening in PerkinElmer’s diagnostics business, which includes products used in COVID-19 testing. In that division, revenue in the first quarter rose by more than 200 percent. However, chief financial officer Jamey Mock told investors that revenue associated with non-COVID products will still rise by about 11 percent this year."

Time to $taple this post clo$ed.